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Better?
Chun-Yi Lu, Li-Min Huang*
The effectiveness of the seven-valent conjugated
pneumococcal vaccine (PCV7) has been repeatedly
demonstrated in many countries. Research in
Taiwan, although limited, has shown similar 
results. Before the introduction of PCV7, pneumo-
coccal pneumonia and empyema were increasing in
Taiwan.1 After the introduction of PCV7 in Taiwan
in October 2005, a 38.5% reduction in the inci-
dence of invasive pneumococcal diseases (IPDs)
was noted.2 The effectiveness of PCV7 has been
largely limited to vaccine-type pneumococcus and
there has been a change of serotype distribution.
The proportion of local clinical isolates covered by
the PCV7 has decreased from 93.4% in 1997–2003
to 73% in 2007.3,4 In certain countries, serotypes
1, 5, and 14 are the most prevalent pneumococcal
serotypes. In Taiwan, however, serotypes 1 and 5
are uncommon. The most common serotypes iso-
lated in 2007 were 19F, 6B, 14, 3 and 23F in chil-
dren aged < 5 years and also in all age groups.4
Serotype 19A has increased markedly from 0.5%
in 2000–2005 to 11.5% in 2006–2008.2 In 2007,
vaccine serotype coverage for children aged 
< 2 years was 65% for PCV7 (7-valent conjugated
pneumococcal vaccine), 65% for PCV10 (10-valent
conjugated pneumococcal vaccine), and 82% for
PCV13. Serotype 19A was a common serotype in
children aged < 2 years (6% of isolates) and 2–4
years (10% of isolates).4
During this period, the PCV7 coverage rates
increased gradually from 0.7% in 2005 to 25.2%
in 2008.2 A larger impact is expected with higher
vaccine coverage rates. By adopting the published
incidences rates of IPDs and pneumococcal/lobar
pneumonia across the country,1,4 we can estimate
the annual case numbers of these two categories
in children aged ≤ 5 years (Table). The protective
efficacy of PCV7 has been established as 97% for
IPD5 and 30% for pneumonia using the criteria
of the World Health Organization.6 With an
80% coverage rate of PCV7, there will be approx-
imately 111 IPD and 123 pneumococcal/lobar
pneumonia cases averted annually in Taiwan.
When PCV10 or PCV13 is used, the number of
cases prevented will probably be higher.
The incidence of IPD peaks at both extremes of
age. Children aged ≤2 years and older people aged
≥ 70 years are most vulnerable. The real incidences
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Table. Incidences of invasive pneumococcal diseases and pneumococcal/lobar pneumonia and episodes
averted if pneumococcal conjugated vaccines are used with an 80% vaccination coverage rate in
children aged ≤ 5 years in Taiwan
Age (yr) 0 1 2 3 4 5 Total
Populationa 187,396 203,590 206,925 211,053 218,019 230,934 1,257,917
Incidence of IPDb (per 100,000) 9.8 9.8 15.6 15.6 15.6 2.2 11.3
Episodes of IPDb 18 20 32 33 34 5 143
Episodes of IPD averted by PCV7c 9 10 18 19 19 3 78
Episodes of IPD averted by PCV13c 13 14 23 24 24 4 102
Incidence of pneumoniad (per 100,000) 22.0 22.0 38.0 42.0 55.0 60.0 40.7
Episodes of pneumoniad 41 45 79 89 120 139 512
Episodes of pneumonia averted by 10 11 19 21 29 33 123
PCV7e
Episodes of pneumonia averted by 14 15 24 27 36 41 159
PCV13e
aAn average of populations in 2007–2009, data acquired from the Minister of the Interior, Taiwan; bincidence and serotype distribution
data obtained from Hsieh et al. [4]; ccalculations were based on efficacy data obtained from Black et al. [5]; dincidence data obtained
from Reference 1; ecalculations were based on efficacy data obtained from Hansen et al. [6]. Serotype distributions were assumed to
be same as that for invasive pneumococcal disease. IPD = invasive pneumococcal disease; PCV7 = seven-valent conjugated pneumo-
coccal vaccine; PCV13 = 13-valent conjugated pneumococcal vaccine.
should be much higher than published figures,
especially in young children and infants, because
blood cultures might not be performed appro-
priately or earlier than antibiotic usage. Early
blood culture is important for the detection of
pathogens in infants and children.
With widespread use of PCVs, the effectiveness
is expected to be even greater due to herd immu-
nity. Herd immunity requires broad vaccination
coverage. Vaccination of only high-risk groups,
which is the current vaccination strategy used in
Taiwan, has a limited impact on disease incidence
in the whole population.
Even with proven effectiveness, the uptake rate
of PCVs has remained far from satisfactory. One
of the obstacles that prevent universal vaccination
with PCVs is the cost. The vaccine is too expensive
for many parents, as well as for the government.
In fact, cost-effectiveness analyses have been done
in many countries and have shown that universal
vaccination with PCV7 in children is cost-saving
only when the current vaccine prices can be signifi-
cantly reduced.7 A Norwegian study has shown
that universal vaccination with three rather than
four doses of PCV7 is cost-saving.8 Norway and cer-
tain other countries, such as the United Kingdom,
Quebec in Canada, and the Liguria region of Italy,
are using a 2 + 1 dosing schedule for universal
PCV vaccination. Studies have shown that vacci-
nation with these schedules is also effective in 
reducing IPDs.9 In Australia, vaccination with
three doses of PCV7 without a booster has been
used successfully. Whether such simplified vac-
cination schedules really work well is worthy of
attention because they provide a significant re-
duction in cost and will probably increase vacci-
nation uptake, especially in countries with lower
economic resources.
Even with widespread use of PCVs, invasive
and non-invasive pneumococcal disease will not
completely disappear and will continue to threaten
child health. The emergence of new “non-vaccine
type” strains is inevitable. Antibiotic resistance
remains an issue in treating pneumococcal dis-
eases. The importance of wise and constrained
antibiotic use cannot be over-emphasized. Besides,
early diagnosis is crucial for successful treatment
of pneumococcal diseases. Recent studies have
suggested that molecular methods could be im-
portant complementary tools for the diagnosis
of pneumococcal diseases and improved patient
care.10
The potential impact of new conjugated pneumococcal vaccines 
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